U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector transforms.
Related Posts
S&P 500 futures inch higher as investors parse earnings reports: Live updates
The three major indexes are coming off a losing session.
Goldman’s view on Friday’s jobs report and how the stock market will react
The stock market may not like an upside surprise in December jobs if it results in higher Treasury yields, according to Goldman.
AI monetization is spreading. UBS shares some of its favorite China plays
Several mainland companies have had a chance at monetizing generative AI in the past two years. Leaders and laggards are emerging.